Rosanne Paul, DO
Dermatology · Bluffton, SCNPI 1588907711
Payments from drug & device makers
Across 77 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$265
- Galderma Laboratories, L.p.$261
- Novartis$181
- Sun Pharmaceutical Industries Inc.$177
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$67
- Sanofi$55
- plus $375 from 11 others
What the payments were for
- Food & beverage$1,28093%
- Education$1007%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $265 |
| Galderma Laboratories, L.p. | 18 | $261 |
| Novartis | 11 | $181 |
| Sun Pharmaceutical Industries Inc. | 4 | $177 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $67 |
| Sanofi | 3 | $55 |
| Lilly USA, LLC | 3 | $54 |
| EPI Health, LLC | 4 | $48 |
| Prugen, Inc. Pharmaceuticals | 3 | $47 |
| UCB, Inc. | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Dermira, Inc. | 2 | $34 |
| Boehringer Ingelheim | 1 | $33 |
| LEO Pharma Inc. | 2 | $28 |
| VYNE Pharmaceuticals Inc. | 1 | $21 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Johnson & Johnson | 1 | $12 |
How this compares
$1,380 in reported general payments places this provider in the 30th percentile of 203 dermatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 23 | $157,595 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $124,785 |
| Humira(Cf) PenAdalimumab | 13 | $90,454 |
| Dupixent PenDupilumab | 25 | $89,116 |
| Dupixent SyringeDupilumab | 21 | $78,187 |
| Pimecrolimus | 21 | $5,601 |
| Clobetasol Propionate | 108 | $4,340 |
| Tacrolimus | 19 | $3,631 |
| Ketoconazole | 229 | $3,046 |
| Clindamycin Phosphate | 56 | $2,861 |
| Metronidazole | 43 | $2,208 |
| Fluorouracil | 19 | $1,799 |
| Triamcinolone Acetonide | 163 | $1,437 |
| Fluocinonide | 25 | $968 |
| Hydrocortisone | 122 | $789 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Bluffton
- Todd SchlesingerCharleston$6.4M
- Matthew MillerGreenville$2.8M
- Marshall ShulerGreenville$2.6M
- Rebecca SmithFort Mill$2.3M
- Amylynne FrankelSpartanburg$1.3M
- Theresa KnoeppAnderson$977K
- Jessica BurgyColumbia$519K
- Richard SturtzAnderson$369K
- John KormanGreer$210K
- Marguerite GermainMt Pleasant$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.